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Abstract
Background: Subjects with head and neck cancer (HNC) often experience post-treatment side effects, particularly
radiation-induced oral mucositis (RIOM). This study aimed to explore the association of Chinese herbal medicine use with
the sequent risk of RIOM among them. Methods: This cohort study used a nationwide health insurance database to identify
subjects newly diagnosed with HNC, aged 20 to 60 years, who received treatment between 2000 and 2007. Among them,
a total of 561 cases received CHM after HNC onset (CHM users); the remaining 2395 cases were non-CHM users. All
patients were followed to the end of 2012 to identify any treatment for RIOM as the end point. Cox proportional hazards
regression was used to compute the adjusted hazard ratio (aHR) of RIOM by CHM use. Results: During the follow-up
period, 183 CHM users and 989 non-CHM users developed RIOM at incidence rates of 40.98 and 57.91 per 1000 personyears, respectively. CHM users had a lower RIOM risk than the non-CHM users (aHR: 0.68; 95% Confidence Interval:
0.58-0.80). The most potent effect was observed in those taking CHM for more than 1 year. Use of Baizhi, Danshen, ShaoYao-Gan-Cao-Tang, Gan-Lu-Yin, Huangqin, Shu-Jing-Huo-Xue-Tang, and Xin-Yi-Qing-Fei-Tang, was significantly related to
a lower risk of RIOM. Conclusion: Findings of this study indicated that adding CHM to conventional clinical care could be
helpful in protecting those with HNC against the onset of RIOM. Further clinical and mechanistic studies are warranted.
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Introduction
Head and neck cancer (HNC), affecting the oral cavity,
pharynx, and larynx, are the eighth most prevalent cancer
type in the world.1 Radiotherapy is a mainstay of treatment administered to more than two-thirds of HNC
patients.2 Nevertheless, they often encounter a common
and debilitating complication characterized by pain and
erythema or ulceration of the oral mucosa due to altered
inflammatory response, namely radiation-induced oral
mucositis (RIOM).3 Research showed that severe RIOM
may lead to swallowing impairment that impacts nutritional intake and treatment noncompliance, thus leading to
placement of feeding tubes and hospitalization.4 Faced
with these dire adverse effects, it is important to seek out

appropriate treatments that could lessen the likelihood of
RIOM or reduce its severity.
To date, no definite intervention has been identified to
efficiently prevent RIOM incidence. Though some supportive modalities, included improving oral hygiene, eliminating local irritants, and frequent rinsing with combination
therapies have been noted; all of these appeared to merely
reduce either the discomfort or the severity of symptoms
after RIOM onset.5,6 However, based on the assertion that
prevention is preferable to mitigation, efforts should be
made to identify active interventions which could reduce
the risk of RIOM and minimize its associated morbidity
after diagnosis of HNC.
As of now, Chinese herbal medicines have recently
attracted global attention due to the reliable therapeutic
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efficacy toward chronic diseases, especially in managing
the symptoms associated with RIOM.7 A herbal formula,
Hangeshashinto, was found to be related to the reduced
infiltration of neutrophils and ofcyclooxygenase-2 in irradiated mucosa, alleviating the discomfort caused by RIOM.8,9
Also worth noting is the fact that previous reports usually
are based on relatively small samples of patients, thus
threatening findings’ representativeness.7 This paucity of
data may be an obstacle to facilitating treatment and prognosis in such cases. Accordingly, this study aimed to assess
the association over time of CHM use with the onset of
RIOM among HNC patients, using a nationwide medical
claims database.

Methods
Data Source
For this study, we used a publicly-released cohort dataset
from the Longitudinal Health Insurance Database (LHID)
in Taiwan. The LHID is a sub-dataset of the National
Health Insurance (NHI) program made up of 1 million randomly sampled patients from 1996 to 2012. Constructed
using a multistage stratified systematic sampling method,
it is a representative sample, on both sex and age, of these
1 million insured individuals and of the general population
of Taiwan.10,11 This cohort database includes (i) personal
information; (ii) health insurance claims data; (iii) diagnostic codes; (iv) prescription drugs registry; (v) socioeconomic data; and (vi) medical examination information on
persons covered under the NHI program. This study was
conducted in accordance with the Helsinki Declaration,
and was approved by the local institutional review board
and ethics committee of Buddhist Dalin Tzu Chi Hospital
(No. B10004021-2).
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Study Participants and Variables
We identified patients with HNC using the corresponding
code in the International Classification of Disease, Ninth
Revision, Clinical Modification (ICD-9-CM) in the diagnosis
field. We selected patients 20 to 60 years old with newly diagnosed HNC and treated with radiotherapy only between 2000
and 2007 (ICD-9-CM codes: 140, 141, 143-148, and 161). To
ensure the identification of HNC patients, only those patients
who also had a Catastrophic Illness Certification (CIC) due to
HNC were included in the study. In Taiwan, insured citizens
with a major disease (eg, schizophrenia, mood disorders,
immune disease, and cancer) can obtain free care for their illness, or related medical conditions, during the certificate’s
validity period. We counted the index date for HNC as the
date on which the patient gained CIC approval. In order to
confirm that all enrolled HNC subjects in this study were incident cases, only new-onset HNC cases were included
(n = 3651). Among them, a total of 402 patients diagnosed
with RIOM before the date of HNC onset were excluded. The
diagnostic algorithm to determine RIOM required at least 3
outpatient visits, or at least 1 inpatient claim for the ICD9-CM codes of 528.01 during the study period. We also
excluded those with missing data and those who were not followed for a minimum of 1 year after HNC diagnosis (n = 293).
After this filtering process, a total of 2956 new-onset HNC
cases were selected for further analysis (Figure 1).
We then utilized the frequency of visits to Chinese medicine physicians to verify the CHM exposure of each
enrollee, because only certified Chinese medicine physicians are allowed to prescribe CHM in Taiwan. Based on
former methods, CHM users were identified as those who
had received CHM to treat HNC for more than 30 days,
whereas those treated for 30 days or less were considered to
be non-CHM users.12-14 In this study, for the CHM user
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3651 patients aged 20-60 years old with newly
diagnosed HNSCC between 2000 and 2007
Subject excluded:
i. 402 patients affected by mucositis before the date of
HNSCC onset
ii. 293 cases with missing data in the baseline
characteristics and those follow-up for less than 1 year

561 were CHM users

2395 were non-CHM
users

183 patients with RIOM

989 patients with RIOM

Figure 1. Flowchart of selection and follow-up of study subjects.

group, the time period between the date of HNC diagnosis
and the date of first CHM use after HNC represented the
immortal time, thus inducing an overestimation of the intervention’s beneficial effect. To reduce this bias, we calculated person-years (PYs) starting from the initiation of
CHM usage to correct for immortal time for subjects who
received CHM.15 Therefore, the index date of the follow-up
period for HNC subjects, classified as non-CHM users, was
assigned to the date of the first HNC diagnosis, whereas the
index date of the follow-up period for CHM users was
assigned to the first date of the initiation of CHM prescription. The end date of follow-up period for both groups was
assigned as the date of the earliest of the following: a diagnosis of RIOM, the date of withdrawal from the insurance
program, or the date of December 31, 2012.

Covariate Assessment
Sociodemographic variables in this study included age,
gender, income (for estimating insurance payments), and
urbanization level of the individual’s residential area.
Monthly income was clarified by the individual insurable
wage and separated into 3 groups, which contained New
Taiwan Dollars (NTD) ≤ 17 880, NTD = 17 881 to 43 900,
and NTD ≥ 43 901. Urbanization levels were divided into
urban (levels 1-2), suburban (levels 3-4), and rural (levels
5-7) areas. Level 1 refers to the “most urbanized” communities and level 7 refers to the “least urbanized” communities.16
Baseline comorbidities for each enrollee were assigned using
the established Charlson-Deyo Comorbidity Index (CCI),17
and based on the individual’s medical records 1 year prior to

initial entry into the cohort. To avoid double counting and
possible over-adjustment in the regression model, HNC was
excluded from the CCI score.

Data Analysis
Categorical variables were reported as percentages, and continuous variables presented as mean values and their standard deviations (SD). An independent t-test and a Chi-square
test were used, as appropriate. To assess the independent
influence of CHM use on the risk of RIOM, we conducted a
Cox proportional hazards regression analysis to calculate the
hazard ratio (HR) after adjusting simultaneously for age,
insurance premium, urbanization level, and CCI. To further
clarify the relation between CHM use and RIOM risk, we
separated the CHM users into those who used CHM for 31
to 365 days and those who used CHM for >365 days. The
Kaplan-Meier method was then employed to plot the cumulative incidence of RIOM for each cohort during the followup period, and the log-rank test was performed to assess the
differences between the 2 curves. Finally, plot values for the
log(−log[survival]) versus the log of survival time were
inspected to verify the proportional hazards assumption. All
analyses were conducted using SAS software version 9.3
(SAS Institute Inc., Cary, NC, USA). Differences of P < .05
were determined to be statistically significant.

Results
We identified 2956 patients with HNC during the period
from 2000 to 2007. Of these, 561 received CHM treatment
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Figure 2. Cumulative incidence of RIOM among HNC patients with and without CHM use.

and 2395 were non-CHM users. Table 1 shows the demographic and clinical characteristics of the 2 groups.
Compared to the non-CHM users, CHM users were more
likely to be male, younger, and have higher CCI scores (all
P < .01).
Among all enrollees, 1172 first episodes of RIOM
occurred, 183 in CHM users and 989 in non-CHM users,
during follow-up periods of 4465.69 and 17 078.67 PYs,
respectively. The incidence rate of RIOM was lower among
CHM users than among non-CHM users (40.98 vs 57.91,
respectively, per 1000 PYs), with an adjusted HR of 0.68
(95% Confidence Interval [CI]: 0.58-0.80; Table 2). Of
note, use of CHM for more than 1 year was associated with
a 36% decreased risk of RIOM (95% CI: 0.49-0.85). The
Kaplan-Meier analysis of survival by days of CHM use
revealed a significantly difference in the survival rate free
from RIOM across the three groups (P < 0.01).
Table 3 presents the results from this analysis stratified
by age and gender. Multivariable stratified analysis verified
that the benefit of CHM therapy in treating RIOM was more
predominant in females than in males, with an adjusted HR

of 0.65 (95% CI: 0.53-0.78; Table 3). Additionally, a more
significant beneficial effect of CHM use was observed
among younger subjects (adjusted HR: 0.55; 95% CI: 0.440.68). The 10 most commonly prescribed herbal formulae
for those with HNC are summarized in Table 4. Among
them, 4 were single-herb products and the rest were multiple-herb products. Cox proportional hazards regression
analysis showed that the use of Baizhi, Danshen, Shao-YaoGan-Cao-Tang, Gan-Lu-Yin, Huangqin, Shu-Jing-HuoXue-Tang, and Xin-Yi-Qing-Fei-Tang was significantly
associated with lower risk of RIOM (Table 4).

Discussion
RIOM is the inflammation of the oral mucosa which presents clinically as edema, erythema, bleeding, ulceration, or
pain. Given that the adverse side effect of RIOM may
influence subsequent antineoplastic treatment, it is of great
significance to prevent or treat RIOM when managing
HNC patients. This is the first evidence-based cohort study
determining whether the integration of CHM into the

Li et al
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Table 1. Demographic Data and Selected Comorbidities of Study Subjects.

Variables

Non-CHM users

CHM users

n = 2395 (%)

n = 561 (%)

1073 (44.8)
1322 (55.2)
53.24±13.43

316 (56.3)
245 (43.7)
47.79 ± 12.81

413 (17.2)
1982 (82.8)

219 (39.0)
342 (61.0)

964 (40.3)
1309 (54.7)
122 (5.1)

213 (38.0)
308 (54.9)
40 (7.1)

1301 (54.3)
420 (17.5)
674 (28.1)

331 (59.0)
99 (17.6)
131 (23.4)

4.00 (7.01)

5.50 (10.14)

P-value
<.001

Age (y)
≤50
>50
Mean (SD)
Gender
Female
Male
Monthly income
Low
Median
High
Residential area
Urban
Suburban
Rural
CCI
Mean (SD)

<.001
<.001

.13

.07

<.001

Abbreviations: CHMs, Chinese herbal medicines; SD, standard deviation; CCI, Charlson-Deyo comorbidity index.

Table 2. Risk of RIOM for HNC Subjects Receiving or Not Receiving CHM Use.
Patient group

Event

PYs

Incidence

Crude HR (95% CI)

Adjusted HR* (95% CI)

Non-CHM users
CHM users
CHM use within 30-365 days
CHM use for more than 365 days

989
183
126
57

17078.67
4465.69
2933.43
1532.26

57.91
40.98
42.95
37.20

1
0.69 (0.59-0.80)
0.72 (0.59-0.86)
0.63 (0.49-0.84)

1
0.68 (0.58-0.80)
0.70 (0.58-0.85)
0.64 (0.49-0.85)

Abbreviations: CHMs, Chinese herbal medicines; PYs, per 1000 person-years; HR, hazard ratio; CI: confidence interval.
*Model adjusted for age, gender, urbanization level, monthly income, and CCI scores.

Table 3. Incidence and Risk of RIOM for HNC Patients Receiving or Not Receiving CHM in the Stratification of Sex and Age.
Non-CHM users
Variables
Gender
Female
Male
Age
≤50 y
>50 y

CHM users

Case

PYs

Incidence

Case

PYs

Incidence

Crude HR (95%
CI)

Adjusted HR (95%
CI)

840
149

13674.22
3404.45

61.43
43.77

114
69

2626.07
1839.62

43.41
37.51

0.69 (0.56-0.83)
0.83 (0.63-1.10)

0.65* (0.53-0.78)
0.81* (0.67-1.09)

465
524

7530.08
9548.6

61.75
54.88

89
94

2663.44
1802.25

33.42
52.16

0.57 (0.47-0.72)
0.98 (0.69-1.09)

0.55** (0.44-0.68)
0.97** (0.66-1.09)

Abbreviations: CHMs, Chinese herbal medicines; PYs, person-years; HR, hazard ratio; CI, confidence interval.
*Model adjusted for age, urbanization level, monthly income, and CCI scores.
**Model adjusted for gender, urbanization level, monthly income, and CCI scores.

conventional therapy could reduce the risk of RIOM in
HNC patients using a large nationwide claims-based database. Over a 10-year follow-up study, we discovered that
HNC patients receiving CHM had a lower likelihood of
RIOM than those not receiving CHM. Furthermore, those

using CHM treatment for more than 1 year were found to
have a markedly lower risk of RIOM by nearly 40%. As
demonstration of a dose-response relationship is considered strong evidence for a causal relationship between
exposure and outcome, this finding suggests that adding
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Salviae Miltiorrhizae Radix et Rhizoma

Dan Shen

Fritillariae Thunbergii Bulbus

Angelicae Sinensis Radix, Glycyrrhizae Radix et Rhizoma,
Paeoniae Radix Alba, Rehmanniae Radix, Atractylodis Rhizoma,
Cyathulae Radix, Citri Reticulatae Pericarpium, Persicae Semen,
Clematidis Radix et Rhizoma, Ligusticum chuanxiong Hort,
Stephaniae Tetrandrae Radix, Notopterygii Rhizoma et Radix,
Angelicae Dahuricae Radix, Gentianae Radix et Rhizoma, Poria
cocos (Schw.) Wolf, Zingiberis Rhizoma
Magnoliae Flos, Lilii Bulbus, Anemarrhenae Rhizoma, Gypsum,
Eriobotryae Folium, Cimicifugae Rhizoma, Ophiopogonis
Radix, Gardeniae Fructus, Scutellariae Radix, Glycyrrhizae
Radix et Rhizoma

Bei Mu

Shu-Jing-Huo-Xue-Tang

*Model adjusted for gender, urbanization level, monthly income, and CCI scores.

Xin-Yi-Qing-Fei-Tang

Scutellariae Radix

Huang Qin

Shao-Yao-Gan-Cao-Tang Paeoniae Radix Alba, Glycyrrhizae Radix et Rhizoma
Gan-Lu-Yin
Rehmanniae Radix, Asparagi Radix, Ophiopogonis Radix,
Dendrobii Caulis, Artemisiae Scopariae Herba, Scutellariae
Radix, Aurantii Fructus, Eriobotryae Folium, Glycyrrhizae
Radix et Rhizoma
Jie Geng
Platycodonis Radix
Yan Hu Suo
Corydalis Rhizoma

Angelicae Dahuricae Radix

Ingredients or generic name

Bai Zhi

CHM name

Anti-inflammatory effect, antimicrobial effect

Antioxidant, anticancer, anti-inflammatory
Attenuates inflammatory and neuropathic
pain
Anti-inflammatory, antioxidant, antibacterial,
antiviral, antitumor activities
antitussive, antiasthmatic properties,
antibacterial activity
Anti-coagulation effect, anti-hypersensitivity
effects, increasing blood circulation, and
relieving pain

Anti-inflammatory, anti-microbial, anti-cancer,
anti-platelet aggregation effects
Improving micro-circulation, antiatherosclerosis, anti-inflammatory
Muscle relaxation
Inhibit cell migration, block angiogenesis,
suppress secretion of inflammatory
cytokines

Function of CHM

Table 4. Risk of RIOM in Relation to the 10 Most Commonly Used Chinese Herbal Medicines for Patients With HNC.

0.59 (0.43-0.89)

0.63 (0.50-0.75)

1702

1636

0.94 (0.75-1.11)

0.67 (0.47-0.88)

0.79 (0.52-1.08)
0.75 (0.50-1.06)

0.67 (0.44-0.93)
0.57 (0.40-0.68)

0.74 (0.52-0.89)

0.69 (0.48-0.92)

Crude HR (95% CI)

1600

1588

1454
1468

1268
1268

1304

1122

Frequency

0.59 (0.41-0.84)

0.64 (0.51-0.78)

0.95 (0.74-1.15)

0.63 (0.46-0.85)

0.77 (0.54-1.10)
0.73 (0.51-1.04)

0.66 (0.45-0.95)
0.54 (0.42-0.70)

0.70 (0.54-0.91)

0.67 (0.49-0.90)

Adjusted HR* (95% CI)

Li et al
CHM to conventional treatment may help lower RIOM
risk. While related studies on this topic are scarce, this
positive therapeutic effect adds to a growing body of literature on the clinical efficacy of CHM use among HNC
patients.7
Findings from this study indicated that younger patients
benefited more from CHM treatment in lowering the risk of
RIOM, irrespective of other factors. This result may be due
to younger people having fewer coexisting medical conditions, having better medical knowledge, having a more
positive attitude toward their medical condition, or having
more psychosocial and coping resources to rely upon than
older patients.18 These findings also suggest that younger
HNC survivors may more easily adapt to the side effects of
treatment, and consequently are at reduced risk of RIOM.
Furthermore, the reduction in risk of RIOM was higher for
females than for males (35% vs 19%). We speculate that
women may have better health literacy, more willingness to
adhere to strict medical procedures, and more positive attitudes about self-care than men,19 and accordingly, they
were more likely to comply with the prescribed medical
regimen to lower risk of RIOM.
Oral mucositis is any inflammatory mucosal destruction
presenting as erythema or ulceration of oral mucosa owing
to the use of chemotherapy or radiation therapy to treat
cancer.3,6,20 Of the 10 most commonly prescribed herbal
formulae for HNC patients, we found that 7 were associated with a significantly lower risk of RIOM. For example,
the use of Xin-Yi-Qing-Fei-Tang was found to lessen the
risk of RIOM by 41%. We speculate that the major ingredient, Anemarrhena asphodeloides, might produce an appreciable anti-inflammatory effect by abating nuclear factor
kappa beta (NF-κB) signaling.21 NF-κB is well known as a
crucial transcription mediator regulating the induction of
the inflammatory response.22 Xin-Yi-Qing-Fei-Tang also
showed an effect against a variety of bacteria,23,24 thus minimizing the risk of bacterial colonization after ulceration
develops.
Use of Shu-Jing-Huo-Xue-Tang and Shao-Yao-GanCao-Tang were also associated with a lower susceptibility
to developing RIOM. Priori studies in a rodent model
showed that both compounds can significantly modulate
the activity of the alpha-2 adrenoceptor (α2-AR).25,26
Dysregulation of the α2-AR pathway may contribute to the
release of inflammatory cytokines, such as tumor necrosis
factor-α (TNF-α), interleukin-1 (IL-1), and IL-6; all of
these mediators have been implicated in the development
of RIOM.6,27
Consistent with the findings of earlier research,14,28 this
study revealed that Gan-Lu-Yin was the most frequently
used Chinese herbal formula for treating HNC. The positive association between Gan-Lu-Yin use and a lower incidence of RIOM may stem from its reported effects that
included reducing cell proliferation and the inhibition of
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inflammatory cytokines through the NF-kB dependent
pathway.29,30 In 1 previous report, relative to untreated
controls, rats fed with Gan-Lu-Yin had markedly reduced
levels of inflammatory markers.30 The inhibition of angiogenesis may prevent the expression and survival of cancer
cells, thereby decreasing the risk of RIOM after HNC
onset.
With regard to the single-herb products used to treat those
with HNC, we noted that Baizhi was associated with a
reduced risk of RIOM events. Recently, several laboratoryidentified, anti-inflammatory, properties of Baizhi have been
reported, including antioxidation,31 anti-inflammatory,32 and
anti-tumor properties.33 Imperatorin, a candidate compound
purified from this CHM product, has been proven to profoundly reduce the release of TNF-α, IL-1β, and IL-6 in
lipopolysaccharide-stimulated RAW 264.7 cells via the suppression of NF-κB activation.32 Additionally, 1 in vitro study
revealed that imperatorin could mediate oncogene expression to induce cell cycle arrest.33
The remaining herbal products suggested as effective in
lessening RIOM risk were Danshen and Huangqin. The
first belongs to the Campanulaceae family, and its ingredient was discovered to possess antioxidant, anti-tumor,
anti-microbial, and immune-boosting properties.34 As for
Huangqin, Wogonin, its main ingredient, has shown antineoplastic and anti-inflammatory effects in both in vitro
and in vivo studies. For example, 1 study demonstrated that
Wogonin can induce AMP-activated protein kinase to
inhibit proliferation and induce apoptosis in cancer cells.35
Wogonin was also found beneficial in suppressing the production of inflammatory mediators by modulating the
NF-κB and NF-E2-related factor 2 signaling pathways.36
These findings may explain the mechanisms responsible
for the potent effects of Danshen and Huangqin observed
in this study.
While our study is the first to investigate the relationship
between CHM use and RIOM risk among patients with
HNC, there are several important limitations. First, using
secondary health care databases always entails the risk of
errors in the coding process. To minimize this bias, we
enrolled only patients with new-onset HNC or RIOM, and
only after the patients had at least 3 outpatient visits or 1
inpatient admission for HNC. Additionally, HNC cases
were further linked to the CIC database to verify their status
as patients with a catastrophic disease. It should also be
noted that the NHI of Taiwan randomly reviews the charts
and audits medical charges to verify the accuracy of claims
files. Moreover, the coding approach and data availability
were similar for the 2 groups, so that any misclassification
bias would have likely been nondifferential. Second, the
LHID lacks information on social network relationships,
smoking, alcohol intake, personality attributes, laboratory
data, and education level. Thus, future research examining
these untested variables is needed to better determine the
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generalizability of our findings. Nevertheless, to thoroughly
address the confounding by indication that may arise in this
real-world comparative effectiveness study, we attempted
to reanalyze the association of CHM use with the risk of
RIOM via a propensity score – matched analysis. For each
HNC patient who received CHM, 1 control patient was
selected by 1:1 matching, based on a propensity score. The
propensity score was calculated using logistic regression on
the basis of patients’ demographics and baseline comorbidities at enrollment. The results of the reanalysis showed that
no significant difference occurred between the 2 groups
with regard to age, sex, monthly income, residential area,
and number of comorbidities after matching procedure with
propensity score, indicating that the 2 groups were comparable on these characteristics (Supplemental Table 1).
Furthermore, the use of CHM was still found to be significantly related to reduction risk of RIOM among HNC participants, with the adjusted HR of 0.65 (Supplemental Table 2).
Third, information regarding dose-limiting toxicity was not
available in this database, and failure to adjust for this factor
might bias the results. To address this issue, a sensitivity
analysis was performed to more carefully examine the
abovementioned association. First, we applied the numbers
of radiotherapy utilization after HNC onset to serve as a
surrogate of dose-limiting toxicities stemming from the
radiation therapy. After considering this variable, in the
multivariate analysis, the results indicated that, as compared to HNC patients without CHM use, the selected
HNC patients with CHM use, still had a significantly lower
risk for RIOM (adjusted HR: 0.70; 95% CI = 0.59-0.82).
Therefore, it can be inferred that the level of dose-limiting
toxicities did not appreciably impact the relationship
reported herein. Fourth, although the findings of this observational cohort study conveyed that the continuous use of
CHM may be beneficial, it must be recognized that participants were not initially randomly categorized into users and
nonusers. Therefore, well-designed randomized controlled
trials are still needed to minimize confounding by covariates
not explicitly accounted for by the present design, thus paving the way for further in vivo studies regarding the effects
of CHM products on patients with other chronic medical
conditions. These limitations notwithstanding, this study
also possessed several strengths. One strength of this nationwide register-based study is the completeness of the records
of hospital diagnoses and prescription claims; the minimal
risk of selection bias and loss to follow-up; and the large
population of both men and women, which provide sufficient power to conduct detailed analyses.

Conclusion
In summary, this large-scale nationwide cohort study
showed that, during treatment for HNC, the integration of
CHM appears to reduce the risk of RIOM by 33%. This

Integrative Cancer Therapies
finding can provide a reference for healthcare providers
seeking therapeutic interventions to improve the prognosis
for HNC patients.
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